BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
BioCentury | Aug 16, 2018
Distillery Techniques

Assays and screens; drug properties

TECHNOLOGY: Cellular assays; toxicology Human kidney cells cultured on decellularized rat kidney extracellular matrix (ECM) scaffolds could be used to screen compounds for nephrotoxicity. The method involved treating rat kidney tissue samples with detergent and...
BioCentury | Aug 10, 2018
Company News

Ironwood ends gout drug deal with AZ

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) terminated its deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) for rights to the pharma's gout drugs Zurampic lesinurad and Duzallo lesinurad/allopurinol. Ironwood said franchise test markets of the drugs did not meet...
BioCentury | Aug 6, 2018
Company News

Ironwood ends gout drug deal with AZ

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) terminated its deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) for rights to the pharma's gout drugs Zurampic lesinurad and Duzallo lesinurad/allopurinol. Ironwood said franchise test markets of the drugs did not meet...
BioCentury | Jul 13, 2018
Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
BioCentury | Jun 29, 2018
Company News

CHMP backs CAR Ts, Orphan candidates

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
BioCentury | May 5, 2018
Finance

Splitting Ironwood

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates...
BioCentury | Oct 20, 2017
Emerging Company Profile

One-upping c-MET

With a plethora of c-MET inhibitors in the clinic for cancer and two on the market, Octimet Oncology N.V. is banking on the dual selectivity of its molecule and its algorithm for identifying responders to...
BioCentury | Aug 28, 2017
Clinical News

FDA approves Ironwood's Duzallo for gout

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said FDA approved Duzallo lesinurad/allopurinol to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone. The company expects to launch the...
BioCentury | Aug 21, 2017
Company News

FDA approves Ironwood's gout combo

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said FDA approved Duzallo lesinurad/allopurinol to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone. The company expects to launch the...
Items per page:
1 - 10 of 95